

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 34635

Title: Access to biologicals in Crohn's disease in ten European countries

Reviewer's code: 00042284

Reviewer's country: South Korea

Science editor: Ya-Juan Ma

Date sent for review: 2017-05-22

Date reviewed: 2017-05-29

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The authors present that the difference of accessibility to biologicals, namely availability, affordability, and acceptability, for Crohn's disease in ten selected European countries and the associations between these dimensions with the uptake of biologicals and economic development. Because limited data exist describing the accessibility to biologics according to economic development, I regard this to be an important study. However, several comments need to be addressed. Major Comments 1. The lack of consideration of the difference in the prevalence of Crohn's disease is a major issue; the prevalence of Crohn's disease varies across European countries as mentioned in the manuscript. Therefore, the number of patients on biologicals per 100000 patients with Crohn's disease could be a better way to demonstrate the uptake of biologicals than the number of patients on biologicals per 100000 population. 2. Please clarify the health insurance system in ten selected European countries. To assess the potential influence of insurance system, compare the differences in the public and private medical insurance systems. 3. Is there any regulation for maintaining biologics? Are there any countries in



BAISHIDENG PUBLISHING GROUP INC

7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

the study that require patients to satisfy criteria for maintaining for biologics? Minor
Comments 1. On page 7, misspelling (last sentence of Introduction).

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 34635

Title: Access to biologicals in Crohn's disease in ten European countries

Reviewer's code: 00506276

Reviewer's country: Poland

Science editor: Ya-Juan Ma

Date sent for review: 2017-05-22

Date reviewed: 2017-06-01

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The aim of this study was to examine the access to biological therapies of the patients with Crohn's disease in 10 European countries. This is a questionnaire-based survey among 10 gastroenterology experts (one in each country). The results are thoroughly analyzed and discussed. The manuscript is well-written. The only concern is that it would be convenient to include some details about the most commonly used biological therapies in CD (their mechanisms of action, efficacy, etc.)